Compare XWIN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XWIN | ANL |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Cayman Islands |
| Employees | 27 | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.3M | 293.4M |
| IPO Year | N/A | 2022 |
| Metric | XWIN | ANL |
|---|---|---|
| Price | $7.16 | $6.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 980.9K | 181.7K |
| Earning Date | 05-14-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.20 | $0.88 |
| 52 Week High | $7.42 | $12.09 |
| Indicator | XWIN | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 79.52 | 36.85 |
| Support Level | $5.58 | $1.36 |
| Resistance Level | N/A | $9.98 |
| Average True Range (ATR) | 0.20 | 0.76 |
| MACD | 0.10 | -0.24 |
| Stochastic Oscillator | 81.27 | 5.56 |
XMax Inc is a designer and lifestyle furniture company. It distributes and retails contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. Its customers mainly comprise distributors and retailers having specific geographic coverages that deploy middle to high-end private label home furnishings. The company operates in one business and industry segment: the design and sale of furniture.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.